TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02931955

Intervention type: OTHER
Intervention: Blood draw, stool collection.
Description: Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.

Intervention type: OTHER
Intervention: Blood draw, stool collection.
Description: Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.

Intervention type: OTHER
Intervention: Blood draw, stool collection.
Description: Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
Study: NCT02388165

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
Study: NCT02727595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyclaPlex Implant
Description: Button and suture type implant that will be implanted between the first and second metatarsal
Study: NCT01720004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated hands-and-knees positioning during labour
Description: Details are in the Arm Description.
Study: NCT02236234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: HPV vaccine
Study: NCT02676700

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training and Kaatsu
Description: The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
Study: NCT03970876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATGC-100
Description: Clostridium Botulinum Type A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Clostridium Botulinum Type A
Study: NCT00705497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Tumor Ablation
Description: Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
Study: NCT04299750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and Alveolar ridge preservation
Description: Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: Tooth extraction and socket natural healing
Study: NCT01321658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric intervention
Description: A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
Study: NCT01855204

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomographic urography
Description: Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed tomographic urography
Description: Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
Study: NCT03105869

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fluorocholine PET/CT
Description: standard diagnostic PET/CT procedure
Study: NCT01529827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT03972735

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychiatric interview
Description: PANSS, MADRS, PSP, YMRS
Study: NCT01529827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO
Study: NCT03972735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical, diagnostic and functional evaluation
Description: ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
Study: NCT01529827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study: NCT03972735

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical, diagnostic and functional evaluation
Description: ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: neuropsychological assessment
Description: WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NECT PROGRAM
Description: Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NECT PROGRAM
Description: Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
Study: NCT02505308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-Potentiated Arginine-Induced Insulin Secretion
Description: Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-Potentiated Arginine-Induced Insulin Secretion
Description: Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
Study: NCT01529827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01438996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197
Description: Vi-CRM197 glycoconjugated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197
Description: Vi-CRM197 glycoconjugated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197
Description: Vi-CRM197 glycoconjugated vaccine
Study: NCT01804348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL-SENSE 1-Step
Description: a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
Study: NCT01529827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study: NCT06419790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT electrode belt, spirometry
Description: Placing electrode belt for EIT monitoring and measuring tidal volume with spirometer
Study: NCT03149497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior approach only in cervical spine trauma
Description: evaluation of efficacy of single approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior approach only in cervical spine trauma
Description: evaluation of efficacy of single approach
Study: NCT02961400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUSH text messages
Description: The intervention is designed to remind participants of treatment components.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PULL text messages
Description: The intervention is designed to remind participants to recall treatment components.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TranS-C
Description: The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TranS-C
Description: The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TranS-C
Description: The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PE
Description: Psychoeducation on the inter-associations between sleep, diet, exercise and stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE
Description: Psychoeducation on the inter-associations between sleep, diet, exercise and stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE
Description: Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
Study: NCT03381352

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemo-radiotherapy with IMRT technique
Description: IMRT radiation technique; 50.4-54Gy/25F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825mg/m2 PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin C 10mg/m2 D1,29 iv
Study: NCT00675311

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DM-Standard
Description: Device/t+ Medical Diabetes Management System

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease Management Plus
Description: Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
Study: NCT03934489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PERSIST
Description: 12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Peer Support
Description: 12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
Study: NCT04341584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter
Study: NCT00766181

Intervention type: BEHAVIORAL
Intervention: Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system
Description: 0.5 mg lidocaine hydrochloride
Study: NCT01800162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Evacuation
Description: Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant Management
Description: Pregnancy will be expectantly managed using serum hcg monitoring.
Study: NCT00939055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StomaphyX
Description: Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: False procedure
Study: NCT02672644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Classic
Description: Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Deep
Description: Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
Study: NCT02374359

Intervention type: OTHER
Intervention: follow-up

Intervention type: OTHER
Intervention: follow-up
Study: NCT02371694

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test drink
Description: The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test drink
Description: The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test drink
Description: The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test drink
Description: The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test drink
Description: The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test drink
Description: The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.
Study: NCT01755390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: infusion solution Route of administration: Intravenous
Study: NCT00444834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 50 mg
Study: NCT00613340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical medial branch blocks
Description: Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical medial branch blocks
Description: Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
Study: NCT01528618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil and cisplatin
Description: The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
Study: NCT04146129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: Single dose of one of four dosages of CDX-0159

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single infusion of normal saline
Study: NCT04394013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: Gentle body stretching with the incorporation of breathing technique

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Mindfulness intervention
Description: Gentle body stretching without the incorporation of breathing technique
Study: NCT03826316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Pharmacokinetic study under fasting conditions
Study: NCT03518775

Intervention type: DEVICE
Intervention: Biometry
Description: Measurement of Cornea

Intervention type: DEVICE
Intervention: Biometry
Description: Measurement of Cornea

Intervention type: DEVICE
Intervention: Biometry
Description: Measurement of Cornea
Study: NCT02000544

Intervention type: DEVICE
Group type: OTHER
Intervention: Modular Cardiopulmonary Bypass Circuit
Description: Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
Study: NCT01428414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 75mg/m2, iv d1, 8,15. qw; 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 75mg/m2, iv d1, 8,15. qw; 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75mg/m2, iv d1, q3w, 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 2, qw, iv d1, 8,15. 4-6 cycles
Study: NCT01996228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator
Study: NCT01965028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS)
Description: High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
Study: NCT03377829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PLA
Description: During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid Surgery
Description: Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.